Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Invested Capital (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Invested Capital for 16 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 22.48% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 22.48% year-over-year, with the annual reading at $1.0 billion for FY2025, 22.48% up from the prior year.
  • Invested Capital hit $1.0 billion in Q4 2025 for Ligand Pharmaceuticals, up from $950.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.0 billion in Q4 2025 to a low of $597.5 million in Q4 2022.
  • Historically, Invested Capital has averaged $798.4 million across 5 years, with a median of $801.1 million in 2024.
  • Biggest five-year swings in Invested Capital: dropped 27.52% in 2023 and later grew 25.94% in 2024.
  • Year by year, Invested Capital stood at $821.3 million in 2021, then decreased by 27.24% to $597.5 million in 2022, then grew by 17.31% to $700.9 million in 2023, then grew by 18.49% to $830.5 million in 2024, then grew by 22.48% to $1.0 billion in 2025.
  • Business Quant data shows Invested Capital for LGNDZ at $1.0 billion in Q4 2025, $950.2 million in Q3 2025, and $827.3 million in Q2 2025.